Testing surufatinib with chemo for advanced pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests adding surufatinib (a targeted therapy) to standard chemotherapy (gemcitabine and nab-paclitaxel) for people with locally advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if the combination helps shrink or control the tumor better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old.
- You must have been diagnosed with pancreatic adenocarcinoma (a common type of pancreatic cancer) that has spread locally but not to distant organs.
- Your tumor cannot be removed by surgery due to how it involves nearby blood vessels.
- You must not have had any prior chemotherapy or other systemic treatment for advanced pancreatic cancer.
- You should be in good physical condition (able to perform daily activities without help, ECOG 0 or 1).
- Your kidney, liver, and blood counts must be within acceptable ranges on recent lab tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether a combination of surufatinib and immunotherapy (camrelizumab, plus an “AS” medicine) can slow or shrink advanced pancreatic cancer that has spread. It is for people starting treatment for advanced disease for the first time and may help those who have measurable tumors and meet safety test limits.
This Phase 2 study tests whether adding surufatinib to first-line treatment (either AG or a similar AG-based regimen) can improve outcomes for people with locally advanced or metastatic pancreatic cancer. You may be considered if your cancer cannot be removed by surgery and you’ve already had a short course of similar treatment with a response.
This trial tests if adding surufatinib to standard chemotherapy before surgery can help people with a certain type of pancreatic cancer. The goal is to see if the combination shrinks the tumor more than chemotherapy alone.
This trial tests a combination of four drugs (surufatinib, camrelizumab, nab-paclitaxel, and gemcitabine) as a first treatment for people whose pancreatic cancer has spread to other parts of the body. The goal is to see if this combination helps shrink tumors and improve survival.
This trial tests a combination of three drugs—surufatinib (a targeted therapy), camrelizumab (an immunotherapy), and a chemotherapy regimen called mFOLFOX6—as a second-line treatment for advanced pancreatic cancer. It's for people whose cancer progressed after first-line gemcitabine-based chemotherapy.
This trial tests if adding two targeted drugs (surufatinib and serplulimab) to standard chemotherapy can shrink locally advanced pancreatic cancer enough to allow surgery. It may help people whose cancer hasn't spread and who haven't had prior treatment.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.